Pacira Biosciences, Inc. (PCRX)

36.81
0.24 0.66
NASDAQ
Prev Close 36.57
Open 36.60
Day Low/High 35.64 / 36.99
52 Wk Low/High 26.95 / 55.00
Volume 410.34K
Exchange NASDAQ
Shares Outstanding 41.23B
Market Cap 1.51B
Div & Yield N.A. (N.A)
Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial

Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced initiation of its Phase 2/3 pivotal trial of EXPAREL ® (bupivacaine liposome injectable suspension) administered as a single-dose injection...

Pacira Pharmaceuticals, Inc. To Present At The UBS Global Life Sciences Conference

Pacira Pharmaceuticals, Inc. To Present At The UBS Global Life Sciences Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the UBS Global Life Sciences Conference at ...

Reduced Pain, Opioid Use, And Opioid-Related Adverse Events In Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl As A Component Of Multimodal Therapy

Reduced Pain, Opioid Use, And Opioid-Related Adverse Events In Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl As A Component Of Multimodal Therapy

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication of results from a pooled analysis of nine clinical trials across five surgical models that compared cumulative pain scores, opioid...

Pacira Pharmaceuticals, Inc. Reports $2.3 Million In Second Quarter EXPAREL® Revenue And Full Second Quarter 2012 Financial Results

Pacira Pharmaceuticals, Inc. Reports $2.3 Million In Second Quarter EXPAREL® Revenue And Full Second Quarter 2012 Financial Results

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the quarter ended June 30, 2012 and provided updates on the commercial launch of EXPAREL® (bupivacaine...

Pacira Pharmaceuticals, Inc. To Present At The Wedbush PacGrow 2012 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. To Present At The Wedbush PacGrow 2012 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Wedbush PacGrow 2012 Life Sciences ...

Pacira Pharmaceuticals, Inc. Announces Timing For Second Quarter 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. Announces Timing For Second Quarter 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company's second quarter ended June 30, 2012, will be released before the market opens on Thursday, August 9, 2012.

7 Stocks Ripping Higher on Huge Volume

7 Stocks Ripping Higher on Huge Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

New Data Quantifying The Effects Of Opioid Use On Patient Care And Economic Outcomes Presented At Key Medical Meetings

New Data Quantifying The Effects Of Opioid Use On Patient Care And Economic Outcomes Presented At Key Medical Meetings

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data that demonstrate opioid-related adverse drug events (ORADEs) following laparoscopic or open gastrointestinal (GI) surgeries increased...

Pacira Pharmaceuticals, Inc. To Present At The Jefferies 2012 Global Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The Jefferies 2012 Global Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2012 Global Healthcare ...

Pacira Pharmaceuticals, Inc. To Be Added To NASDAQ Biotechnology Index

Pacira Pharmaceuticals, Inc. To Be Added To NASDAQ Biotechnology Index

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index® (NASDAQ: NBI) effective today.

Pacira Pharmaceuticals, Inc. To Present At Bank Of America Merrill Lynch 2012 Health Care Conference

Pacira Pharmaceuticals, Inc. To Present At Bank Of America Merrill Lynch 2012 Health Care Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that James Scibetta, chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2012 Health Care...

Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing

Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has secured a $27.

Pacira Pharmaceuticals, Inc. Announces Timing For First Quarter 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. Announces Timing For First Quarter 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company's first quarter ended March 31, 2012, will be released before the market opens on Wednesday, May 9, 2012.

HP, Eldorado Gold, Pacira Are Market Movers

HP, Eldorado Gold, Pacira Are Market Movers

HP, Eldorado Gold, Pacira, Tractor Supply are among big market movers Thursday

Pacira Pharmaceuticals, Inc. Prices Public Offering Of Common Stock

Pacira Pharmaceuticals, Inc. Prices Public Offering Of Common Stock

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $9.

Avid Technology: After-Hours Trading

Avid Technology: After-Hours Trading

These stocks drew trading interest in Wednesday's extended session.

Pacira Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock

Pacira Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that it has commenced an underwritten public offering of shares of its common stock.

Pacira Pharmaceuticals, Inc. Announces Commercial Availability Of EXPAREL®

Pacira Pharmaceuticals, Inc. Announces Commercial Availability Of EXPAREL®

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the commercial launch of EXPAREL ® (bupivacaine liposome injectable suspension) in the United States.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Pacira Pharmaceuticals, Inc. Reports 2011 Financial Results

Pacira Pharmaceuticals, Inc. Reports 2011 Financial Results

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced consolidated 2011 financial results, reviewed key 2011 accomplishments and reiterated that it expects to initiate the commercial launch of EXPAREL ® ...

Pacira Pharmaceuticals, Inc. Announces Timing For 2011 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. Announces Timing For 2011 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc (Nasdaq: PCRX) today announced that financial results for the company's fourth quarter and year ended Dec.

Pacira Pharmaceuticals, Inc. To Present At Barclays Capital Global Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At Barclays Capital Global Healthcare Conference

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Barclays Capital Global Healthcare ...

Pacira Pharmaceuticals, Inc. To Participate In RBC Capital Markets Global Healthcare Conference

Pacira Pharmaceuticals, Inc. To Participate In RBC Capital Markets Global Healthcare Conference

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to participate in a panel titled “New Developments in ...

Pacira Pharmaceuticals, Inc. Provides Update On Commercial Launch And Product Availability Timing For EXPAREL®

Pacira Pharmaceuticals, Inc. Provides Update On Commercial Launch And Product Availability Timing For EXPAREL®

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updated timing for its commercial launch of EXPAREL ® (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by...

7 Stocks Under $10 Moving Higher

7 Stocks Under $10 Moving Higher

These under-$10 stocks are making huge-percentage moves to the upside today.

Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge

Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge

Pacira must convince hospitals that its long-acting painkiller benefits patients and saves them money.

Biotech Calendar: Key Dates for October

Biotech Calendar: Key Dates for October

Here's a list of October's potentially stock-moving biotech events.

Biotech Stock Mailbag: Adventrx Pharma

Biotech Stock Mailbag: Adventrx Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

10 Best-Performing IPOs of 2011

10 Best-Performing IPOs of 2011

These new issues have outperformed the broader market, and some have more than doubled.

10 Health-Care Stocks Outperforming the Index

10 Health-Care Stocks Outperforming the Index

These health-care stocks delivered attractive returns in the past one month, outperforming the index.

TheStreet Quant Rating: C (Hold)